|
Abstract To observe the clinical efficacy of Xiaojin tablets combined with mifepristone for treating women with abdominal pain because of uterine fibroids. Methods: 104 women with abdominal pain because of uterine fibroids were selected and divided into study group and control group (52 cases in each group) according to the random number table method from January 2017 to January 2019. The women in the control group were treated with mifepristone, and the women in study group were treated with mifepristone combined with Xiaojin tablets. The clinical efficacy, the fibroid volume, main symptom scores, and the levels of serum biochemical indicators, such as follicular growth hormone (FSH), luteinizing hormone (LH), estradiol (E2), progesterone (P), estrogen receptor (ER), progesterone receptor (PR), and vascular endothelial growth factor (VEGF) after 3 months of treatment, and the recurrence rate after 6 months of treatment were compared between the two groups. Results: After 3 months of treatment, the total effective rate of women in study group was significant higher than that of women in control group, the fibroid volume of women in the two groups after treatment had reduced significantly, and the fibroid volume of women in the study group was 7.32±1.57 cm3, which was significant less than that (12.36±2.03 cm3) of women in control group (P＜0.05). After treatment, the scores of main symptoms of lower abdominal pain, and the rates of breast tenderness, prolonged menstruation, menometrorrhagia, and fatigue of women in the two group had decreased significantly, and those of women in the study group were significant lower than those of women in control group (P＜0.05). After treatment,the levels of serum FSH, LH, E2, P, ER, PR and VEGF of women in the two group had decreased significantly, and those of women in the study group were significant lower than those of women in control group (P＜0.05). Within 6 months after discontinuation drugs used, the recurrence rate of women in study group was 7.7%, which was significant lower than that (40.4%) of women in the control group (P＜0.05). There was no significant difference in the incidence of adverse reaction between the two groups (P>0.05). Conclusion: Xiaojin tablets combined with mifepristone for treating women with uterine fibroids is safe and effective, which can help reduce abdominal pain and other symptoms, improve hormones levels, and reduce the risk of recurrence.
|
|
|
|
|
|
